Mecasermin Dosage
Medically reviewed by Drugs.com. Last updated on May 15, 2020.
Applies to the following strengths: 10 mg/mL
Usual Pediatric Dose for:
Additional dosage information:
Usual Pediatric Dose for Primary IGF-1 Deficiency
Initial dose: 0.4 to 0.8 mg/kg subcutaneously 2 times a day for at least 7 days
Maximum dose: 0.12 mg/kg subcutaneously 2 times a day
Comments:
-Not a substitute to growth hormone (GH) for approved GH indications.
Uses: Treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dose Adjustments
-The dosage should be individualized for each patient.
-May increase by 0.04 mg/kg per dose if initial dose is well-tolerated for at least one week.
-Doses over 0.12 mg/kg have not been evaluated, and should not be used due to hypoglycemic effects.
-Reduce dose if hypoglycemia occurs with recommended doses despite adequate food intake.
Precautions
CONTRAINDICATIONS:
-Hypersensitivity to any of the ingredients
-Closed epiphyses
-Malignant neoplasia or a history of malignancy
Safety and efficacy have not been established in patients younger than 2 years or older than 64 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
-Rotate injection sites with each injection (upper arm, thigh buttock, or abdomen).
-Administer shortly before or after (within 20 minutes) a meal or snack.
-Hold dose if the patient is unable to eat shortly before or after a dose for any reason.
-Do not increase dose to make up for one or more omitted dose.
-Administer using a disposable syringe of small enough volume to accurately withdraw the dose.
-If using syringes that measure dose in units, convert dose using the following formula: Weight (kg) x Dose (mg/kg) x 1 mL/10 mg x 100 units/1 mL = units/injection.
Storage requirements:
-Keep refrigerated; protect from light.
-Avoid freezing.
-Use within 30 days of first vial entry.
-Discard any unused product after 30 days.
Reconstitution/preparation techniques:
-Solution should be clear.
-Do not use if solution is cloudy or has particulate matter.
Monitoring:
-Preprandial glucose monitoring is recommended at treatment initiation and until a well-tolerated dose is established.
-Continue preprandial glucose monitoring for frequent hypoglycemia symptoms or severe hypoglycemia.
Patient advice:
-Educate patients/caregivers on how to recognize the signs of hypoglycemia.
-Educate patients/caregivers on the symptoms of serious allergic reactions and the need to seek prompt medical attention should such a reaction occur.
-If an allergic reaction occurs, treatment should be discontinued.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about mecasermin
Consumer resources
Other brands: Increlex
